SCHEMBL377005

SCHEMBL377005

NC(=NS(=O)(=O)c1ccc(F)c([N+](=O)[O-])c1)c1ccc(N2CCC(=Cc3ccccc3-c3ccccc3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 16/20 0.48
BCL2 P10415 9/20 0.48
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
MITF O75030 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503559 1.00 BCL2L1 (0.48) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL377004 1.00 BCL2L1 (0.48) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL13503523 0.88 BCL2L1 (0.48) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL376987 0.88 BCL2L1 (0.48) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL13503884 0.87 BCL2L1 (0.39) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL376416 0.84 BCL2L1 (0.45) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL13503904 0.84 BCL2L1 (0.45) BCL2L1BCL2ALDH1A1LMNASMN1; SMN2
SCHEMBL376984 0.83 BCL2L1 (0.57) BCL2L1BCL2
SCHEMBL13503556 0.83 BCL2L1 (0.57) BCL2L1BCL2
SCHEMBL376985 0.83 BCL2L1 (0.57) BCL2L1BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885ALDH1A1 2354/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD BCL2L1 18/4885BCL2 2/4885ALDH1A1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.